## Abstract ## BACKGROUND The authors attempted to determine the maximum tolerated dose (MTD) of gemcitabine in combination with etoposide and cisplatin as a chemotherapy regimen and investigated the safety and antitumor activity with the recommended doses of gemcitabine with etoposide and cisplat
โฆ LIBER โฆ
Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma
โ Scribed by Urakami, Shinji; Fujii, Yasuhisa; Yamamoto, Shinya; Yuasa, Takeshi; Kitsukawa, Shinichi; Sakura, Mizuaki; Yano, Akihiro; Saito, Kazutaka; Masuda, Hitoshi; Yonese, Junji; Fukui, Iwao
- Book ID
- 120224617
- Publisher
- Elsevier Science
- Year
- 2014
- Tongue
- English
- Weight
- 195 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1078-1439
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Phase I/II study of a combined gemcitabi
โ
Tetsuro Tsukamoto; Junji Yonese; Yuhei Ohkubo; Iwao Fukui
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 112 KB
Impact of C-reactive protein kinetics on
โ
Kazutaka Saito; Shinji Urakami; Yoshinobu Komai; Yosuke Yasuda; Yuichi Kubo; Shi
๐
Article
๐
2012
๐
John Wiley and Sons
๐
English
โ 304 KB
Phase II trial of combinationnab-paclita
โ
Alva, Ajjai; Daignault, Stephanie; Smith, David C.; Hussain, Maha
๐
Article
๐
2013
๐
Springer US
๐
English
โ 191 KB
1866 THE EFFICIENCY OF SECOND-LINE CHEMO
โ
Nishihara, Chikako; Kuratsukuri, Katsuyuki; Iguchi, Taro; Tamada, Satoshi; Tanak
๐
Article
๐
2013
๐
Lippincott Williams and Wilkins
๐
English
โ 130 KB
Concurrent cisplatin/gemcitabine chemoth
โ
J. Umanzor; M. Aguiluz; C. Pineda; S. Andrade; M. Erazo; Claudio Flores; Sergio
๐
Article
๐
2006
๐
Elsevier Science
๐
English
โ 139 KB
Docetaxel/cisplatin as first-line chemot
โ
Martina Baur; Heinz-Roland Kienzer; Johannes Schweiger; Maria DeSantis; Erich Ge
๐
Article
๐
2002
๐
John Wiley and Sons
๐
English
โ 69 KB
๐ 1 views
## Abstract ## BACKGROUND The objective of this Phase II study was to assess the clinical activity and toxicity of docetaxel (D) and cisplatin (P) in patients with locally advanced unresectable, metastatic, or recurrent squamous cell carcinoma of the head and neck (SCCHN). ## PATIENTS Of 34 pati